Table 1. Main characteristics of all studies included in the meta-analysis.
| First author | Year | Country | Genotyping method | Cancer type | Source of controls | Case | Control | Plymorphisms |
|---|---|---|---|---|---|---|---|---|
| Song, H. | 2013 | China | PCR-RFLP | Non-Hodgkin lymphomas | Hospital | 496 | 512 | −1516G/T,−574G/T,+4259T/G |
| Li, Z. | 2013 | China | PCR-RFLP | Hepatocellular carcinoma | NA | 271 | 318 | −1516G/T |
| Bai, J. | 2013 | China | PCR-RFLP | Non-small-cell lung cancer | Population | 432 | 466 | −1516G/T,−574G/T,+4259T/G |
| Tong, D. | 2012 | China | PCR-RFLP | Pancreatic cancer | Hospital | 306 | 422 | −1516G/T,−574G/T,+4259T/G |
| Li, Z. | 2012 | China | PCR-RFLP | Hepatocellular carcinoma | NA | 144 | 182 | −574G/T,+4259T/G |
| Cai, C. | 2012 | China | PCR-RFLP | Renal Cell Carcinoma | Hospital | 322 | 402 | −1516G/T,−574G/T,+4259T/G |
| Cao, B. | 2010 | China | PCR-RFLP | Gastric cancer | Hospital | 212 | 252 | −1516G/T,−574G/T,+4259T/G |
PCR-RFLP: PCR-restriction fragment length polymorphism; NA: not available.